Ipca Laboratories: Inaugural BRSR, GRI Report and First EcoVadis Rating
Ipca Laboratories Limited

At a Glance
- Industry: Pharmaceutical manufacturing (formulations and APIs)
- Company: Listed (NSE: IPCALAB)
- Headquarters: Mumbai, India
- Employees: 17,335
- Global presence: 120+ countries
- Sites in scope: 17 plants and 5 offices in India; 2 plants and 5 offices abroad
- Services: BRSR reporting, materiality assessment, sustainability reporting, EcoVadis, GHG accounting, ESG data management platform
- Headline results: inaugural BRSR for FY 2022-23; GRI-aligned Sustainability Report for FY 2023-24; "Committed" rating in its first EcoVadis assessment
About the Client
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, with a portfolio of more than 350 formulations and 80 Active Pharmaceutical Ingredients (APIs) supplied to over 120 countries.
With Oren's support, Ipca published its inaugural Business Responsibility and Sustainability Report (BRSR) for FY 2022-23. It then developed a Sustainability Report aligned with the Global Reporting Initiative (GRI) Standards and took part in the EcoVadis assessment for the first time.
The Challenge
- Inconsistent data collection: without standard data templates across its locations, Ipca's ESG data was inconsistent and slow to aggregate and analyse.
- Stakeholder coordination: aligning internal teams, suppliers, investors and regulators on ESG priorities was difficult.
- Materiality: Ipca needed a structured way to identify and prioritise material topics, benchmarked against the Indian API and formulation sectors.
- Environmental measurement: energy, emissions, water, waste and biodiversity impacts needed a more reliable, data-driven framework.
Oren's Solution
- Materiality assessment and stakeholder engagement: Oren ran a materiality assessment with internal teams and external stakeholders, identifying the ESG topics most critical to Ipca's business.
- Organisational boundaries and asset mapping: Oren defined reporting boundaries and mapped every facility in scope: 17 plants and 5 offices in India, and 2 plants and 5 offices abroad.
- Centralised ESG and GHG data: Oren implemented Oren Sustainability Hub so Ipca can collect, process and analyse sustainability data from all locations in one place.
The Outcome
| Year | Impact Area | Outcome |
|---|---|---|
| FY 2022-23 | BRSR | Inaugural BRSR published in line with SEBI's requirements. |
| FY 2023-24 | Sustainability Report | GRI-aligned Sustainability Report developed and designed by Oren. |
| FY 2023-24 | EcoVadis | "Committed" rating achieved in Ipca's first EcoVadis assessment. |
| Ongoing | Data Management | ESG and GHG data from all 29 plants and offices in India and abroad managed on Oren Sustainability Hub, supporting each annual BRSR. |
In the Client's Words
"With Oren's guidance and innovative technological solutions, we successfully navigated the complexities of data management, tackled obstacles related to stakeholder engagement and materiality assessment, and effectively quantified our environmental impacts, resulting in the seamless publication of our inaugural BRSR report."
Ankit Gupta, Assistant Regional Manager, Ipca
Conclusion
In two reporting cycles, Ipca Laboratories went from no standard ESG templates to an inaugural BRSR, a GRI-aligned Sustainability Report and its first EcoVadis rating, all built on one data system covering its plants and offices in India and abroad. Ipca continues to work with Oren on its annual BRSR reporting and ESG strategy.
Related services: BRSR reporting · EcoVadis · Materiality assessment · ESG for pharmaceuticals

